Essentials for physicians and health care professionals ordering and - - PowerPoint PPT Presentation

essentials for physicians and health care professionals
SMART_READER_LITE
LIVE PREVIEW

Essentials for physicians and health care professionals ordering and - - PowerPoint PPT Presentation

Essentials for physicians and health care professionals ordering and interpreting urinary screens for drugs of abuse. Dr. Edward Randell Disclosure of Potential for Conflict of Interest FINANCIAL DISCLOSURE Grants/Research Support: CIHR and


slide-1
SLIDE 1

Essentials for physicians and health care professionals ordering and interpreting urinary screens for drugs of abuse.

  • Dr. Edward Randell
slide-2
SLIDE 2

Disclosure of Potential for Conflict of Interest

FINANCIAL DISCLOSURE Grants/Research Support: CIHR and others. Speakers Bureau/Honoraria: None Consulting Fees: None Other: Employee of Memorial University

slide-3
SLIDE 3

Learning Objectives

  • Describe why urine is the preferred sample for

drug of abuse screening

  • Describe common interfering substances
  • Identify factors to consider when interpreting

positive and negative drug screens

  • Describe the strengths and limitations of

common techniques used for urine drug screening

slide-4
SLIDE 4

Why are UDS important to clinical practice?

  • Can identify more non-adherent patients than

monitoring behavior and self-reporting alone

  • Identify new or recurrent drug misuse
  • Support clinical decisions
  • Assist diagnosis
  • Deterrent and provide objective evidence of

abstinence in high risk patients

slide-5
SLIDE 5

Why is interpreting UDS correctly important?

  • UDS screen interpretation carries significant

potential for harm if done incorrectly

  • False accusations of drug abuse or diversion

based on misinterpretation of UDS results carry potential medicolegal consequences.

Health care professionals who effectively employ UDS have a good understanding of the pharmacology of commonly encountered drugs and work closely with lab professionals when ordering and interpreting these tests

slide-6
SLIDE 6

Drug Screens

Common Drug of Abuse

Amphetamines and Methamphetamine Opiates Benzodiazepines Cocaine Barbiturates Methadone Phencyclidine Marijuana Oxycodone

slide-7
SLIDE 7

Introduction

Check out discuss of similar case at: http://paindr.com/two-puffs-too-bad-demystifying- marijuana-urine-testing/

A 40 years old female receiving Oxycodone, presents to a pain clinic for routine follow-up visit. A random urine drug screen is done by immunoassay and she tests positive for Marijuana (cannabinoids positive). When asked, she admits “I only smoked two puffs five days ago”. Fact or Myth?

slide-8
SLIDE 8

Quiz: 7 UDS questions

What is detected in the urine following:

  • 1. Acetaminophen/Codeine administration
  • 2. Morphine administration
  • 3. Heroine use
  • 4. Poppy seed consumption
  • 5. 2nd hand exposure to Marijuana smoke
  • 6. Explain a negative drug screen result for a patient on

chronic opioid therapy…

  • 7. On receiving a negative result on an opiate screen for a

patient you prescribed hydromorphone you would…

slide-9
SLIDE 9
  • To determine level of UDS interpretative

knowledge of physicians who use UDS to monitor adherence on chronic opioid therapy

  • 7 question survey given to 114 physicians
  • 77 who use UDS regularly
  • 37 who didn’t

Reisfield, G. M., Bertholf, R., Barkin, R. L., Webb, F., & Wilson, G. (2006). Urine drug test interpretation: what do physicians know?. Journal of opioid management, 3(2), 80-86.

slide-10
SLIDE 10

Reisfield, G. M., Bertholf, R., Barkin, R. L., Webb, F., & Wilson, G. (2006). Urine drug test interpretation: what do physicians know?. Journal of opioid management, 3(2), 80-86.

slide-11
SLIDE 11

Reisfield, G. M., Bertholf, R., Barkin, R. L., Webb, F., & Wilson, G. (2006). Urine drug test interpretation: what do physicians know?. Journal of opioid management, 3(2), 80-86.

slide-12
SLIDE 12
  • 99 internal medicine residents
  • Compared personal confidence with

interpreting drug screens vs. measured performance.

Starrels, J. L., Fox, A. D., Kunins, H. V., & Cunningham, C. O. (2012). They don’t know what they don’t know: Internal medicine residents’ knowledge and confidence in urine drug test interpretation for patients with chronic pain. Journal of general internal medicine, 27(11), 1521-1527.

slide-13
SLIDE 13

Starrels, J. L., Fox, A. D., Kunins, H. V., & Cunningham, C. O. (2012). They don’t know what they don’t know: Internal medicine residents’ knowledge and confidence in urine drug test interpretation for patients with chronic pain. Journal of general internal medicine, 27(11), 1521-1527.

There was no significant differences in interpreting drug screens among medical residents stating confidence in their ability versus those acknowledging lack of confidence.

slide-14
SLIDE 14

Brief History of Drug screening

1950’s blood “tox screens” 1960’s TLC 1970’s IA and POC testing 1980’s IA + GC-MS 21st Century LC- MS/MS

1950’s Emergency Rooms and Death investigations 1970’s: Addiction treatment & criminal justice 1970’s Methadone maintenance/Opioid Treatment/Military Workplace/Industry/Govt. Highway safety

slide-15
SLIDE 15

The Technology used for UDS

slide-16
SLIDE 16

How are DOAs screened?

Immunoassay GC-MS (Gas Chromatography coupled to Mass Spectrometry) LC-MS (Liquid Chromatography coupled to Mass Spectrometry)

slide-17
SLIDE 17

Actually the following list is more accurate

Method Common Abbreviation Cloned enzyme donor immunoassay CDIA Enzyme-linked immunosorbent assay ELISA Enzyme-multiplied immunoassay technique EMIT Fluorescence polarization immunoassay FPIA Radioimmunoassay RIA Point of care testing methods POCT Gas Chromatography Mass Spectrometry GC-MS Liquid Chromatography Ultraviolet Detection HPLC-UV Liquid Chromatography High Resolution Mass spectrometry LC-hrMS Liquid Chromatography tandem mass spectrometry LC-MS/MS Liquid Chromatography time-of-flight mass spectrometry LC-TOF Thin Layer Chromatography TLC

slide-18
SLIDE 18

Immunoassay Urine Drug Screens (UDS)

  • Uses antibodies specific for drug or common

metabolite target

  • Detection of a drug depends on antibody

specificity, cut-off, and drug concentration.

  • Immunoassay-based Lab Methods
  • Automated on laboratory analyzers
  • Immunoassay-based POCT devices
  • Presence of band indicates a positive result
slide-19
SLIDE 19

GC-MS

Barbosa, S. S., Leal, F. D., Padilha, M. C., Silva, R. S., Pereira, H. M. G., Aquino Neto, F. R., & Silva Júnior, A. I. D. (2012). Specificity and selectivity improvement in doping analysis using comprehensive two-dimensional gas chromatography coupled with time-of-flight mass spectrometry. Química Nova, 35(5), 982-987.

slide-20
SLIDE 20

LC-MS/MS

20

Eichhorst, J. C., Etter, M. L., Rousseaux, N., & Lehotay, D. C. (2009). Drugs of abuse testing by tandem mass spectrometry: a rapid, simple method to replace immunoassays. Clinical biochemistry, 42(15), 1531-1542.

slide-21
SLIDE 21

UDS techniques are targeted or untargeted

Targeted drug screens - identify specific drugs to screen excluding most others.

  • Most common: Immunoassay & LC-MS/MS
  • All UDS commonly used in NL are targeted.

Untargeted drug screens – are broad drug screens without exclusion.

  • GC-MS and LC-hrMS methods are untargeted.
slide-22
SLIDE 22

Comparison of UDS techniques

Screening Screening/Confirmatory Analysis Immunoassay GC-MS or LC-MS/MS Ability to detect drug class (Sensitivity) Low to nil for synthetic opioids but fair for others High Ability to discriminate drug from similar compounds (Specificity) Variable-false positives and false negatives High Use Qualitative screen Quantitative confirmation Cost Variable Variable TAT rapid Many days Application Works best for screening drug- free population; may be less useful in pain-management. Definitive & Legally defensible Interpretation Complex Complex

slide-23
SLIDE 23

Why urine?

slide-24
SLIDE 24

Why is urine the most used sample?

  • Easy to obtain
  • Minimal preparation
  • Most drugs of interest & their metabolites

concentrate in urine

  • Good sensitivity and specificity for recent use
  • Wider window of detection compared to blood
slide-25
SLIDE 25

Positivity in urine indicates exposure ...But

  • Does not correlate with clinical status
  • Can miss very recent exposure
  • Positivity means different things depending on

the screening method used.

slide-26
SLIDE 26

Interpreting urine drug screens

Urine Drug Test Positive Negative

Patient reports taking the drug

Yes

True Positive

  • 1. Patient is taking the drug as

reported.

  • 2. Test detects the substance

reported False Negative

  • 1. Patient may be mistaken about

taking the drug.

  • 2. Last dose too low or too long ago to

be detected.

No

False Positive

  • 1. Interfering substance
  • 2. Unreported self-

administration of a cross- reacting substance True Negative

  • 1. Patient is not taking the drug as

reported.

  • 2. UDS does not detect the substance.
slide-27
SLIDE 27

UDS Interpretation

Factors Affecting UDS interpretation

Time since ingestion

Duration of use

Administration Route Urine volume Hydration Status

Amount of drug ingested

Diet

Urine pH

Concurrent Medications

Urinary frequency

Testing Method

Dosage Intervals

Disease State Body Weight

Individual metabolism

slide-28
SLIDE 28

Interpreting UDS

  • Unexpected interferences
  • Target Compounds
  • Cut-offs
  • Windows of Detection
  • Importance of considering drug metabolism
slide-29
SLIDE 29

Common Immunoassay Interferences

Target Drugs Interfering Drugs Amphetamines Diet Pills, Vicks inhaler (US), Trazodone, Aripiprazole, Promethazine and Phentermine Marijuana Efavirenz (Antiretroviral), baby shampoo and soap, pantoprazole and possibly other proton pump inhibitors Hydromorphone Hydrocodone Methadone Quetiapine Fentanyl Trazodone TCAs Quetiapine Opiates/Morphine Poppy Seeds, Quinolone antibiotics Benzodiazepines Sertraline PCP Venlafaxine

slide-30
SLIDE 30

Agents that can cause positive results on amphetamine immunoassay.

Moeller, K. E., Lee, K. C., & Kissack, J. C. (2008, January). Urine drug screening: practical guide for clinicians. In Mayo Clinic Proceedings (Vol. 83, No. 1,

  • pp. 66-76). Elsevier

Cross-reactivity is a common problem for UDS relying on immunoassay technique.

slide-31
SLIDE 31

Moeller K E et al. Mayo Clin Proc. 2008;83:66-76

slide-32
SLIDE 32

Different methods have different targets

Drug/Class Immunoassay Screen Mass Spectrometry Benzodiazepines Oxazepam Specific Drugs: Diazepam, Oxazepam, Loraxepam, Temazepam, Alprazolam, Clonazepam… Opiates Morphine Specific Drugs: Morphine, Codeine, Oxycodone, Fentanyl, Hydromorphone…. Cocaine Cocaine Metabolite Cocaine and Benzoeconine Marijuana THC metabolite THC and THC-COOH Amphetamine & Methamphetamine Amphetamine & Methamphetamine Specific Drugs: Amphetamine, MDA, MDMA, metamphetamine…

Some Mass Spectrometry methods are non-targeted – meaning that they detect “everything” and both suspected and unsuspected can be explored.

slide-33
SLIDE 33

Moeller K E et al. Mayo Clin Proc. 2008;83:66-76

For both Morphine and Codeine

Different methods have different cutoffs.

Cutoffs determine the drug concentration at which a positive result is reported. This is not the same as a detection limit.

slide-34
SLIDE 34

For how will a UDS remain positive?

Most- 1 to 3 days Some (marijuana, diazepam, ketamine, PCP) may be detected for a week or more Depends of urine concentration of drug and assay cutoff

slide-35
SLIDE 35

Excretion pattern of Cocaine

2000 4000 6000 8000 10000 12000

10 20 30 40 50 60

Cocaine (base) 42 mg smoked

Benzoyleconine Ecgonine Methyl ester Cocaine

Cone, E. J., Sampson-Cone, A. H., Darwin, W. D., Huestis, M. A., & Oyler, J. M. (2003). Urine testing for cocaine abuse: metabolic and excretion patterns following different routes of administration and methods for detection of false-negative results. Journal of analytical toxicology, 27(7), 386-401

Detected by immunoassay (300 µg/L)

slide-36
SLIDE 36

Marijuana (Heavy use) (Moderate use) Benzodiazepines (Long acting)

Barbiturate (long acting)

Window of detection in urine

2 days 4 days 6 days 1 week 2 weeks (Short acting)

(Short)

(Single use) Amphetamine & Metamphetamine Alcohol and Phencyclidine

Moeller K E et al. Mayo Clin Proc. 2008;83:66-76

Cocaine

slide-37
SLIDE 37

Meperidine

Window of detection in urine

1 days 2 days 3 days

Methadone

Oxycodone Morphine from Heroine Morphine

Moeller K E et al. Mayo Clin Proc. 2008;83:66-76

Codeine 4 days Up to 6 days if metabolite tested Heroine only a few hours Often missed Often missed

slide-38
SLIDE 38

Window of detection based on sample type.

Minutes Hours Days Weeks Months Years Blood Saliva Urine Sweat Hair

slide-39
SLIDE 39

Drug Metabolism must be considered

Benzodiazepine assays are prone to false negatives.

slide-40
SLIDE 40

Drug metabolism must be considered.

slide-41
SLIDE 41

Implication of cutoffs and cross- reactivity to immunoassay.

Smith, M. L., Shimomura, E. T., Summers, J., Paul, B. D., Nichols, D., Shippee, R., ... & Cone, E. J. (2000). Detection times and analytical performance of commercial urine opiate immunoassays following heroin administration. Journal of Analytical Toxicology, 24(7), 522-529.

slide-42
SLIDE 42

Drugs detected by opioid screens using mass spectrometry

Drug Mass Spectrometry Heroine 6 monoacetyl morphine Morphine Codeine Codeine Morphine Hydrocodone Oxycodone Oxycodone Oxymorphone Hydrocodone Poppy Seeds Morphine Hydrocodone Hydrocodone Hydromorphone Fentanyl Fentanyl Norfentanyl

slide-43
SLIDE 43

Most drug screens identify opiates not opioids

Opioid

  • Chemicals that work by

binding opioid receptors

  • Opiates + semisynthetic
  • Heroin, hydrocodone,

Hydromorphone,

  • xycodone, Fentanyl,

Meperidine,…

Opiate

  • Natural alkaloids derived

from opium poppy

  • Codeine and Morphine

Many Opioids and Benzodiazepines are missed by routine immunoassay UDS.

slide-44
SLIDE 44

Interpretation

Negative for prescribed medication

Diversion Patient run out of medication Patient not taking full amount Sample tampering Immunoassay testing (false negative)

slide-45
SLIDE 45

Interpretation

Positive for un- prescribed medication

Drug Abuse Testing error: False Positive (poppy seeds) Laboratory error: testing or clerical Variability: within and between patients Immunoassay testing

slide-46
SLIDE 46

Open communication with lab is required…

  • 1. The clinical value of UDS depends on the level
  • f interaction between the ordering physician

and testing lab.

  • 2. Appropriate lab use requires consideration of:
  • 1. The purpose of the UDS
  • 2. Why, who, and when the test is done
  • 3. The limits of the lab results
  • 4. What is meant in lab reporting terminology
  • 5. The significance of screening cutoffs
slide-47
SLIDE 47

How people beat drug tests

  • 1. Substitution with synthetic urine or

“purchased” drug free urine

  • 2. Flush out with commercially available product
  • 3. Adulteration by adding reactive or masking

substance to the urine

  • 1. Visine eye drops, Salt, Oxidizing agents, Potassium

Nitrite, glutaraldehyde.

slide-48
SLIDE 48

Finding Cheats: A few simple tests

Sample Temperature

  • 90 to 100 for first 4 minutes

pH

  • Should be 4.5 to 8

Creatinine

  • Should be >3 mmol/L

Nitrite

  • Negative
slide-49
SLIDE 49

Conclusions

slide-50
SLIDE 50

Quiz: 7 UDS questions

What is detected in the urine following:

  • 1. Acetaminophen/Codeine administration
  • 2. Morphine administration
  • 3. Heroine Use
  • 4. Poppy seed consumption
  • 5. 2nd hand exposure to Marijuana smoke
  • 6. Explain a negative drug screen result for a patient on

chronic opioid therapy.

  • 7. On receiving a negative result on an opiate screen for a

patient you prescribed hydromorphone you would…

(Codeine & Morphine) (Morphine) (6 monoaceylmorphine & Morphine) (Morphine) (Nothing) (Which opioid? Screen may not measure.) (Most screens do not measure hydromorphone. Request confirmatory procedure)

slide-51
SLIDE 51

Effective UDS use depends on:

Good relationship with Lab Know which test lab is using Insure screening results are confirmed before serious action Choose testing strategy based on purpose of testing Know recent medication history Insure proper collection and labelling

slide-52
SLIDE 52

References

Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA, 315(15), 1624-1645. Moeller, K. E., Lee, K. C., & Kissack, J. C. (2008). Urine drug screening: practical guide for clinicians. In Mayo Clinic Proceedings (Vol. 83, No. 1, pp. 66-76). Elsevier Hammett-Stabler, C.A., Weber, L.R. (2008) A Clinical Guide to Urine Drug Testing. CME monograph available at http://ccoe.rbhs.rutgers.edu/online/ARCHIVE/endurings/09MC07.pdf Reisfield, G. M., Bertholf, R., Barkin, R. L., Webb, F., & Wilson, G. (2006). Urine drug test interpretation: what do physicians know?. Journal of opioid management, 3(2), 80-86. Starrels, J. L., Fox, A. D., Kunins, H. V., & Cunningham, C. O. (2012). They don’t know what they don’t know: Internal medicine residents’ knowledge and confidence in urine drug test interpretation for patients with chronic pain. Journal of general internal medicine, 27(11), 1521-1527. Pesce, A., West, C., Egan-City, K., & Clarke, W. (2012). Diagnostic accuracy and interpretation of urine drug testing for pain patients: an evidence-based approach. In Toxicity and drug testing.